Project Grant R21AI194021
Award Date 8/25/25
Completion Date 7/31/27
Dollars Obligated $155K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- The federal Project Grant award of $153,000.00, funded by the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310), is focused on investigating potential radiomitigating strategies for gastrointestinal acute radiation syndrome (GI-ARS) resulting from high-dose ionizing radiation exposure. The key objectives of this research project are: To assess the mitigating effects of dietary methionine restriction on GI-ARS following radiation exposure using an animal...
- The U.S. Department of Health and Human Services' National Institutes of Health (NIH) awarded a $149,008 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. to evaluate PEG-BPEI as a potential mitigator against gastrointestinal acute radiation syndrome (GI-ARS). The project aims to develop a murine model of partial body irradiation that simulates GI injury while sparing a portion of the...
- The federal Project Grant award of $164,500.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310), awarded on August 19, 2025, supports the development and validation of human normal tissue patient-derived organoids (NT-PDOs) for pre-screening new candidate gastrointestinal (GI) radiation countermeasures. The goal is to create an extracorporeal model based on healthy human GI tissue to enable high-throughput screening of radiomitigators while accounting...
- This federal Project Grant award of $158,716 from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports research to investigate the epigenetic and transcriptional mechanisms underlying intestinal stem cell fate conversion in response to severe radiation injury. The project aims to comprehensively examine the epigenetically-regulated and transcriptionally-dependent transitions, and the molecular factors that enable a "revival stem...
- This Project Grant award of $157,000 was provided by the U.S. Department of Health and Human Services' National Institutes of Health (NIH) through the Trans-NIH Research Support program (CFDA 93.310). The funding supports the development of UTS-1401, a novel small molecule agent, as a medical countermeasure to mitigate hematopoietic acute radiation syndrome (H-ARS) following a radiation mass casualty event. The research, conducted by the collaborative partnership of Henry Ford Health and...
- This Project Grant award of $156,000.00 was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Georgetown University. The project aims to develop a novel, dual-specimen biomarker strategy to improve the early detection of gastrointestinal acute radiation syndrome (GI-ARS), a critical condition arising from ionizing radiation exposure. The research will evaluate angiotensin-converting enzyme 2 (ACE2) as an early, tissue-specific...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel medical countermeasure to treat the deadly gastrointestinal acute radiation syndrome (GI-ARS). The $167,500 award to The Feinstein Institutes for Medical Research, a non-profit medical research organization, will fund a 2-year project to investigate MSP68 as a mitigator of GI-ARS and its ability to promote the...
- This $157,400 Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports the development of an effective medical countermeasure against gastrointestinal acute radiation syndrome (GI-ARS). The project aims to establish the efficacy of certain biocompatible amphiphilic block copolymers, developed by Maroon Biotech Corp, in increasing 10-day and 30-day survival rates as well as preserving gut barrier function in a...
- This is a Cooperative Agreement awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Old Dominion University (ODU) and its research foundation, Odurf, to develop a radiation mitigator called YK-4-250 for treating gastrointestinal acute radiation syndrome (GI-ARS). The $552,787 award aims to investigate the mechanisms by which YK-4-250, a novel Tempol-ARB conjugate, can mitigate GI-ARS and potentially expanded applications as a broader...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $164,000.00 in funding to Albany Medical College to conduct research on specialized pro-resolving lipid mediators for developing systemic radiation countermeasures. The project aims to address the urgent and unmet clinical need to limit radiation-induced damage in the event of a nuclear incident. Specifically, the research will investigate how pro-resolving lipid...